Table 3 Model-estimated proportion of patients with episodic and chronic migraine with maintained response

Response rate

Galcanezumab 120 mg

(N = 436)

Galcanezumab 240 mg

(N = 428)

Placebo

(N = 875)

 75% Response ≥3 consecutive months^b

19.7%

21.3%

8.5%

  Odds ratio (95% CI)

2.7 (1.9, 3.7)^*

2.9 (2.1, 4.1)^*

 75% Response all 6 months

6.2%

6.8%

1.8%

  Odds ratio (95% CI)

3.5 (1.9, 6.3)^*

3.9 (2.1, 6.9)^*

 100% Response ≥3 consecutive months^b

3.7%

6.5%

2.7%

  Odds ratio (95% CI)

1.4 (0.7, 2.5)

2.5 (1.4, 4.2)^*

 100% Response all 6 months

0.7%

1.4%

0.2%

  Odds ratio (95% CI)

2.9 (0.8, 10.4)

5.3 (1.6, 17.1)^†

Chronic migraine^c

Galcanezumab 120 mg

(N = 273)

Galcanezumab 240 mg

(N = 274)

Placebo

(N = 538)

 30% Response all 3 months

29.3%

29.2%

16.4%

  Odds ratio (95% CI)

2.1 (1.5, 3.0)^*

2.1 (1.5, 3.1)^*

 75% Response all 3 months

2.6%

2.9%

2.0%

  Odds ratio (95% CI)

1.3 (0.6, 3.1)

1.5 (0.6, 3.4)